January 6, 2017 / 2:19 PM / 7 months ago

BRIEF-Teva projects more than $750 mln in sales in U.S. product launches in 2017

Jan 6 (Reuters) - Teva Pharmaceutical Industries Ltd -

* Teva CEO: we continue to see challenges as a company and as an industry and we expect some of these challenges to continue in 2017: conf call

* Teva CEO: "2016 was a transition year, 2017 will be a year of execution": conf call

* Teva CEO: we expect to produce more than 1000 new generic products launches in 2017: conf call

* Teva CEO: one priority is to defend Copaxone in the face of an important pending legal milestone: conf call

* Teva CEO: we are projecting more than $750 million in sales in U.S. product launches in 2017: conf call

* Teva CEO: I recognize that the gap between the outlook we gave you July and the guidance presented today is disappointing : conf call

* Teva expects Copaxone 2017 revenue of $3.8 billion to $3.9 billion (assuming no 40 mg generic): conf call

* Teva says it will take price increases on a generic drug if the opportunity arises: conf call

* Teva we assume two competitors for Concerta in 2017: conf call

* Teva CEO says $750 million in new drug launches in the U.S. is a conservative number: conf call

* Teva says we have no plans to change dividend policy: conf call

* Teva CEO says we see a decline in specialty business revenue contribution to net revenue in 2017: conf call

* Teva says application for generic Advair is expected to be submitted in 2018: conf call

* Teva: many potential launches were not realized in 2nd half 2016 & that has a carry over effect in 2017 & so we decided to lower expectations for 17'

* Teva: today we are generating $300 million in biosimilar revs, and expect partnership with Celltrion to almost double that in the next couple of years

* Teva CEO: the bigger number of shots on goal now... Will enable us to risk-adjusted better going forward Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below